

DATE:	2022 March 21
TO:	North, Edmonton and Central Zones
FROM:	Alberta Precision Laboratories (APL) – North Sector, University of Alberta Hospital
RE:	New First and Second Trimester Prenatal Risk Assessment Requisitions

PLEASE POST OR DISTRIBUTE AS WIDELY AS APPROPRIATE

Key Message

- **Effective immediately new First and Second Trimester Prenatal Risk Assessment Requisitions are available for use.**

Why this is important

- Individual requisitions have been created for First Trimester Prenatal Risk Assessment and Second Trimester Prenatal Risk Assessment.
- Clinical data fields required for First Trimester Prenatal Risk Assessment have been clarified:
 - Ethnic Background choices
 - Previous pregnancy with a common aneuploidy now include Trisomy 18 and Trisomy 13 in addition to Trisomy 21
 - Diabetes treatment choices
 - Chorionicity choices for twin pregnancies
- Clinical data fields required for Second Trimester Prenatal Risk Assessment have been clarified:
 - Ethnic Background choices
- Format changes have been made to improve readability.

Action Required

- The new requisitions can be obtained from the APL or DynaLIFE websites
 - [First Trimester Prenatal Risk Assessment Requisition \(albertahealthservices.ca\)](https://www.albertahealthservices.ca/frm-21909.pdf)
 - [Second Trimester Prenatal Risk Assessment Requisition \(albertahealthservices.ca\)](https://www.albertahealthservices.ca/frm-21908.pdf)
- Effective immediately discard all previous versions of the Maternal Prenatal Screen Requisition and use these requisitions to order First and Second Trimester Prenatal Risk Assessments.
- Patients in Central Zone with first trimester prenatal risk assessment performed in Calgary should continue to use [REQ9080FTS First Trimester Combined Screen FTS Blood Work \(albertahealthservices.ca\)](#)

Inquiries and feedback may be directed to

- Genetic Counsellors, University of Alberta Hospital, 780-407-7907
- Miranda Brun, PhD, Clinical Biochemist, University of Alberta Hospital, 780-722-4123, miranda.brun2@albertaprecisionlabs.ca

This bulletin has been reviewed and approved by

- Dr. Kareena Schnabl, Section Chief, Clinical Biochemistry, APL North Sector
- Dr. Michael Mengel, Medical Director, APL North Sector
- Dr. Dennis Bulman, Medical/Scientific Director, Genetics and Genomics, APL